Pacira BioSciences Inc (PCRX)
30.27
-0.55
(-1.78%)
USD |
NASDAQ |
May 15, 14:20
Pacira BioSciences Free Cash Flow: 173.19M for March 31, 2024
Free Cash Flow Chart
Historical Free Cash Flow Data
Date | Value |
---|---|
March 31, 2024 | 173.19M |
December 31, 2023 | 139.49M |
September 30, 2023 | 130.25M |
June 30, 2023 | 126.68M |
March 31, 2023 | 104.65M |
December 31, 2022 | 115.20M |
September 30, 2022 | 92.70M |
June 30, 2022 | 102.44M |
March 31, 2022 | 103.95M |
December 31, 2021 | 79.85M |
September 30, 2021 | 98.06M |
June 30, 2021 | 82.87M |
March 31, 2021 | 38.76M |
December 31, 2020 | 39.23M |
September 30, 2020 | 28.38M |
June 30, 2020 | 13.12M |
March 31, 2020 | 58.36M |
December 31, 2019 | 60.36M |
September 30, 2019 | 57.93M |
June 30, 2019 | 53.34M |
March 31, 2019 | 43.71M |
December 31, 2018 | 34.36M |
September 30, 2018 | 27.23M |
June 30, 2018 | 6.831M |
March 31, 2018 | -5.744M |
Date | Value |
---|---|
December 31, 2017 | -1.481M |
September 30, 2017 | -0.869M |
June 30, 2017 | 15.14M |
March 31, 2017 | 15.31M |
December 31, 2016 | 8.744M |
September 30, 2016 | 4.188M |
June 30, 2016 | -10.38M |
March 31, 2016 | -13.70M |
December 31, 2015 | -12.27M |
September 30, 2015 | -14.29M |
June 30, 2015 | -3.469M |
March 31, 2015 | 3.38M |
December 31, 2014 | 3.58M |
September 30, 2014 | -12.02M |
June 30, 2014 | -30.59M |
March 31, 2014 | -47.83M |
December 31, 2013 | -56.01M |
September 30, 2013 | -72.22M |
June 30, 2013 | -75.12M |
March 31, 2013 | -84.66M |
December 31, 2012 | -88.39M |
September 30, 2012 | -72.56M |
June 30, 2012 | -65.26M |
March 31, 2012 | -52.79M |
December 31, 2011 | -37.17M |
Free Cash Flow Range, Past 5 Years
13.12M
Minimum
Jun 2020
173.19M
Maximum
Mar 2024
84.94M
Average
87.78M
Median
Free Cash Flow Benchmarks
Arbutus Biopharma Corp | -78.92M |
Ligand Pharmaceuticals Inc | -19.62M |
Chimerix Inc | -64.44M |
Karyopharm Therapeutics Inc | -117.73M |
FibroGen Inc | -274.68M |
Free Cash Flow Related Metrics
Cash from Operations (Quarterly) | 49.10M |
Cash from Investing (Quarterly) | -15.53M |
Cash from Financing (Quarterly) | -2.817M |
Free Cash Flow Per Share (Quarterly) | 0.8864 |
Free Cash Flow to Equity (Quarterly) | 48.37M |
Free Cash Flow to Firm (Quarterly) | 46.26M |
Free Cash Flow Yield | 10.16% |